News / US / cnbc
Rare Disease Families Face Regulatory Hurdles in Quest for Gene Therapy Access
Health Technology · Biotechnology · cnbc · 2026-09-10
GILD
The struggle of the Stecker family to secure gene therapy for their son highlights the systemic challenges and ethical dilemmas in treating rare childhood diseases.
What Happened
Systemic Barriers in Rare Disease Treatment: The development of gene therapies for rare conditions like Batten disease faces significant hurdles, including high manufacturing costs and small patient populations that deter investors. Regulatory requirements for large-scale, long-term clinical trials often clash with the urgent needs of patients who are rapidly losing their vision and cognitive abilities.
The Evolution of Gene Therapy Development: Initial excitement surrounding gene therapy for CLN3 Batten disease cooled as biotech firms struggled with complex FDA requirements and funding shortages. After Amicus Therapeutics returned the rights to the therapy, the industry highlighted the difficulty of creating sustainable business models for treatments targeting only a few hundred patients.
Ethical Dilemmas in Compassionate Use: Families seeking access to unproven treatments through the FDA's expanded access program often encounter resistance from companies concerned about trial integrity and equitable distribution. The ethical tension between maintaining strict clinical trial standards and providing life-altering interventions for children on the verge of total disability remains a central conflict.
Advocacy and Future Outlook: Despite the systemic failures, parents continue to act as powerful advocates, pushing for regulatory flexibility and faster pathways to treatment. Neela Therapeutics is currently working with the FDA to design a new trial, offering a glimmer of hope for patients like Wheeler Stecker who are running out of time to preserve their remaining vision.